Noor Siddiqui
CEO
Orchid
Orchid utilizes whole genome sequencing to detect rare genetic disorders in embryos, identifying risks associated with monogenic and polygenic diseases before pregnancy. This technology enables prospective parents to make informed decisions by providing comprehensive genetic data that traditional screening methods often miss.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$16.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional preimplantation genetic testing (PGT) methods analyze a limited portion of an embryo's DNA, potentially missing critical genetic risks. This incomplete screening can leave prospective parents unaware of potential monogenic and polygenic diseases that could affect their future child.
Solution
Orchid offers whole genome sequencing for embryos, providing a comprehensive analysis of over 99% of an embryo's DNA to detect a wider range of genetic disorders. This advanced screening technology identifies risks associated with both monogenic diseases (caused by a single gene mutation) and polygenic diseases (influenced by multiple genes), including neurodevelopmental disorders, cancers, and heart conditions. By providing more complete genetic data, Orchid enables prospective parents to make more informed decisions during in vitro fertilization (IVF) and select the embryo with the lowest risk for specific diseases. The service includes expert review of the genetic data and consultation with a board-certified genetic counselor to explain the findings and discuss specific risks related to each embryo tested.
Target Audience
Orchid's primary customers are prospective parents undergoing IVF who want to maximize their chances of having a healthy child by screening for a wide range of genetic risks.
Features
- Whole genome sequencing of embryos, analyzing over 99% of the DNA
- Detection of monogenic diseases, including neurodevelopmental disorders, cancers, and birth defects
- Screening for polygenic risk predispositions, such as Alzheimer's disease, heart disease, and certain cancers
- Comprehensive reports combining results from PGT-A, PGT-M, and PGT-P in a single analysis
- Expert review of genetic data by a team of specialists
- Consultation with a board-certified genetic counselor to explain findings and discuss risks